Besides the trouble in midcaps and smallcaps, investors in pharma stocks were also left disappointed last week. Nifty Pharma Index slipped over 3% during the week. Aurobindo Pharma and Lupin tanked about 15% each, while Sequent Scientific dropped 13%. Analysts don’t seem to be excited enough by their quarterly report cards.
Is this the beginning of the end of the pharma bull run? In today’s special podcast with independent market expert Rajiv Nagpal, we try to understand the pain points for investors in the pharma pack.
Listen in.
Welcome to the show Mr Nagpal.
1) Can you explain the key factors behind the weakness in pharma stocks last week? Is it all about pricing pressure in the US market?
2) Do you see downgrades in the offing in most pharma stocks?
3) What cues have you picked up from concalls on earnings outlook?
4) Do you think it is a good time to buy the dip in select pharma stocks or should one sit on the sidelines?
Thank you Mr Nagpal. That’s all in today’s special podcast. But do keep checking this space for more such interesting content. Good bye!
